Sanofi: presents phase II data for fitusiran
(CercleFinance.com) - Sanofi has presented positive intermediate long-term safety and efficacy data from the phase II open-label extension study of fitusiran in people with hemophilia A or B, with or without inhibitors.
This presentation was made today as part of a session dedicated to research on the World Federation of Hemophilia Virtual Summit.
Fitusiran, a new RNAi therapeutic agent in development, has the potential to transform the treatment of hemophilia, at a monthly dose subcutaneously in people with hemophilia A or B, with or without inhibitors.
Long-term exploratory data shows that a prophylactic treatment with fitusiran achieves a sustained reduction in the annual rate of bleeding in patients with moderate-to-severe hemophilia A or B, with or without inhibitors.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
This presentation was made today as part of a session dedicated to research on the World Federation of Hemophilia Virtual Summit.
Fitusiran, a new RNAi therapeutic agent in development, has the potential to transform the treatment of hemophilia, at a monthly dose subcutaneously in people with hemophilia A or B, with or without inhibitors.
Long-term exploratory data shows that a prophylactic treatment with fitusiran achieves a sustained reduction in the annual rate of bleeding in patients with moderate-to-severe hemophilia A or B, with or without inhibitors.
Copyright (c) 2020 CercleFinance.com. All rights reserved.